Witryna18 mar 2024 · The Company is developing IMVT-1401, a novel fully human monoclonal antibody, which is in Phase II a clinical trials for the treatment of myasthenia gravis and thyroid eye disease ("TED"), also ... Witryna2 lut 2024 · After agreement with regulators regarding protocol modifications, the company intends to continue to pursue development of IMVT-1401. Immunovant has traded in a range of $8.34 to $53.75 in the ...
Roivant Invests $200 Million in Immunovant to Advance ... - BioSpace
WitrynaAn Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED) ... (TED) Informations générales. Numéro EudraCT : 2024-002839-66. Witryna8 lis 2024 · The company is developing IMVT-1401 with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”). A pivotal... finneas real name
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 …
Witryna2 lut 2024 · The Company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients in Phase 2b ASCEND GO-2 trial in Thyroid Eye Disease (TED). Witryna30 cze 2024 · A small proof of concept phase IIa multicenter, open-label, single-arm clinical trial (ASCEND-GO 1, NCT03922321) evaluated two weekly 680 mg subcutaneous doses of IMVT-1401 followed by four weekly 340 mg subcutaneous doses of IMVT-1401 in seven adult patients with moderate-to-severe, active TED. IMVT … Witryna19 kwi 2024 · Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) The safety and scientific validity of this study is … finneas song